Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial

Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG).

(2019) Arjun Vasant Balar et al.   JOURNAL OF CLINICAL ONCOLOGY

Long term oncologic outcome in patients with bladder cancer after radical cystectomy: Impact of carcinoma in situ in the era of neoadjuvant chemotherapy

(2019) Erfan Amini et al.   INTERNATIONAL UROLOGY AND NEPHROLOGY

Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancer

(2019) Marcus J. Daniels et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Bacillus Calmette-Guérin Salvage Therapy

(2019) Badrinath R. Konety et al.   UROLOGIC CLINICS OF NORTH AMERICA

Treatment Options for Patients with Recurrent Tumors After BCG Therapy: Are We Ignoring the Obvious?

(2018) Roger Li et al.   EUROPEAN UROLOGY

Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease

(2018) Roger Li et al.   EUROPEAN UROLOGY

Intravesical rAd–IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin–Refractory or Relapsed Non–Muscle-Invasive Bladder Cancer: A Phase II Randomized Study

(2017) Neal D. Shore et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline

(2017) Sam S. Chang et al.   JOURNAL OF UROLOGY

Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon α2b Formulated in Syn3 for Failures of Bacillus Calmette–Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer

(2016) Neema Navai et al.   ANNALS OF SURGICAL ONCOLOGY

Contemporary 90-day mortality rates after radical cystectomy in the elderly

(2014) J. Schiffmann et al.   EJSO

Phase II Trial of Intravesical Nanoparticle Albumin Bound Paclitaxel for the Treatment of Nonmuscle Invasive Urothelial Carcinoma of the Bladder after bacillus Calmette-Guérin Treatment Failure

(2014) James M. McKiernan et al.   JOURNAL OF UROLOGY

SWOG S0353: Phase II Trial of Intravesical Gemcitabine in Patients with Nonmuscle Invasive Bladder Cancer and Recurrence after 2 Prior Courses of Intravesical Bacillus Calmette-Guérin

(2013) Eila C. Skinner et al.   JOURNAL OF UROLOGY

Phase I Trial of Intravesical Recombinant Adenovirus Mediated Interferon-α2b Formulated in Syn3 for Bacillus Calmette-Guérin Failures in Nonmuscle Invasive Bladder Cancer

(2013) Colin P.N. Dinney et al.   JOURNAL OF UROLOGY

Interferon alfa in the treatment paradigm for non–muscle-invasive bladder cancer

(2013) Donald Lamm et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Clinical Trial Design for the Development of New Therapies for Nonmuscle-invasive Bladder Cancer: Report of a Food and Drug Administration and American Urological Association Public Workshop

(2013) Jonathan P. Jarow et al.   UROLOGY

Long-Term Survival Outcomes with Intravesical Docetaxel for Recurrent Nonmuscle Invasive Bladder Cancer After Previous Bacillus Calmette-Guérin Therapy

(2012) LaMont J. Barlow et al.   JOURNAL OF UROLOGY

Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin

(2012) Colin P.N. Dinney et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS